How XERMELO can help
How XERMELO was studied
In the TELESTAR study, XERMELO + somatostatin analog (SSA) was compared with SSA injections alone in 90 people (45 per test group) with carcinoid syndrome diarrhea (CSD). Participants were having between 4 to 12 bowel movements (BMs) per day and were already on a steady SSA dose for at least 3 months. All participants were followed for 12 weeks and recorded diarrhea frequency in a daily diary.
XERMELO pills + SSA injections provide long-term relief for CSD
TELESTAR, the clinical study that led to the FDA approval of XERMELO, showed meaningful reductions in CSD symptoms. XERMELO was studied in multiple long-term safety studies. The average treatment was 92 weeks.

XERMELO + SSA reduced average daily BM frequency 2X more than SSA injections alone (-1.4 vs -0.6, respectively).
Give XERMELO 12 weeks to work
In the TELESTAR study, almost 9 out of 10 people with CSD (89%) taking XERMELO pills plus SSA injections had a reduction in diarrhea frequency at 12 weeks. In the same study, only 69% of patients on SSA injections alone reduced their BM frequency.

XERMELO reduced serotonin levels
CSD occurs when there is too much serotonin in the gut. When serotonin breaks down in your body, it becomes 5-hydroxyindoleacetic acid (5-HIAA). People with CSD often have high levels of 5-HIAA. About 25% of patients who enrolled in the TELESTAR study had normal 5‑HIAA levels, and the remaining 75% had elevated levels.
At the end of the TELESTAR study, patients' 5-HIAA levels were measured. In the group treated with XERMELO + SSA injections, 5-HIAA levels were reduced by 40.1 mg. In patients treated with SSA alone, 5‑HIAA levels showed an increase of 11.5 mg.
Your doctor may measure your 5-HIAA to see how much serotonin is in your body.


How to talk to your doctor about XERMELO
Complete a few questions and download your answers to create a helpful discussion guide for your next appointment.
Create discussion guide